GLP-1s and Hepatic Events; ‘Shame, Taboo, Hygiene’; Treating Late-Onset IBD

Among U.S. adults with diabetes and steatotic liver disease in the All of Us cohort, new use of a GLP-1 receptor agonist was linked with a 38% to 42% lower risk of hepatic events over nearly 3 years of median follow-up. (American Journal of Gastroenterology)

Measures of frailty and functional capacity in cirrhosis patients can predict future hospitalization, according to a prospective cohort study. (Clinical Gastroenterology and Hepatology)

A rapid abbreviated non-contrast MRI protocol for detecting hepatocellular carcinoma (HCC) in patients with cirrhosis under surveillance had far higher sensitivity (94.6% vs 51.4%) and specificity (96.6% vs 69.5%) versus ultrasound in a single-center study. (Hepatology)

Researchers in JAMA Network Open examined rural-urban disparities in HCC incidence and mortality in the U.S.

Spontaneous viral suppression in patients with chronic hepatitis D was more common in men and those with diabetes, but less common for those with higher initial levels of hepatitis D virus (HDV) RNA, hepatitis B surface antigen, and alanine aminotransferase. (Hepatology)

A 20-year analysis of liver transplants showed that recipients with both HDV and hepatitis B virus (HBV) had more advanced disease and tended to receive organs at a younger age compared with recipients who only had HBV. However, the co-infected group had higher post-transplant survival rates. (Clinical Gastroenterology and Hepatology)

Privacy, hygiene, taboo, and shame were cited as the top reasons for withholding defecation in school among Dutch children. (JAMA Network Open)

In a randomized trial, translumbosacral neuromodulation therapy proved safe and showed significant benefit for fecal incontinence and bowel symptoms over a sham intervention. (Gastroenterology)

Norovirus sickened 115 people aboard a Princess Cruises ship that recently sailed through the Caribbean, according to the CDC. (NBC News)

Meanwhile, passengers unaffected by a norovirus outbreak on a British cruise ship have been allowed off the ship in the French port city of Bordeaux. (AP)

The FDA approved zenocutuzumab (Bizengri) for previously treated advanced, unresectable, or metastatic cholangiocarcinoma in patients who harbor a NRG1 gene fusion.

Systemic advanced therapies for inflammatory bowel disease (IBD) showed benefits for cutaneous or musculoskeletal manifestations of the disease as well, a systematic review and meta-analysis showed. (Inflammatory Bowel Diseases)

A U.K. analysis looked at therapeutic choices in late-onset IBD. (Inflammatory Bowel Diseases)

The time-dependent HelPSCore prognostic score can help identify high-risk primary sclerosing cholangitis, according to a multicenter prospective study. (Clinical Gastroenterology and Hepatology)